This is the authors' abstract. We don't add key points for this paper.
Acne vulgaris is a prevalent chronic inflammatory skin disorder that significantly impacts patients’ quality of life and necessitates effective and safe therapeutic strategies. This article presents an analysis of current scientific sources and clinical experience regarding the use of the novel fourth-generation topical retinoid trifarotene (50 μg/g cream) in combination with systemic doxycycline for the treatment of moderate to severe papulopustular acne. A systematic review of scientific data highlights the unique mechanisms of trifarotene, particularly its high selectivity for the retinoic acid receptor gamma (RAR-γ). The antibacterial and anti-inflammatory properties of doxycycline, which enhance trifarotene’s therapeutic effects by inhibiting Cutibacterium acnes proliferation and reducing inflammatory cytokine production, are also discussed. The authors share their clinical experience, demonstrating the high efficacy and favorable safety profile of this combined treatment in patients with moderate facial and truncal acne. The combination of trifarotene (50 μg/g) and systemic doxycycline offers proven clinical benefits, good tolerability, and a low risk of adverse events. Collective evidence from both Russian and international studies supports the recommendation of trifarotene and doxycycline combination therapy as an effective and safe approach with strong potential for widespread implementation in contemporary dermatologic practice.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Snarskaya et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: